Medications for the treatment of cocaine addiction: Focus on glutamatergic compounds

Natali E. Nemirovsky, Michael Olive

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Scopus citations

Abstract

Cocaine potently increases monoaminergic neurotransmission by inhibitingpresynaptic dopamine, norepinephrine, and serotonin transporters. However, a wealth ofevidence now exists that implicates an important role of the excitatory amino acidneurotransmitter glutamate and its receptors in the rewarding and reinforcing effects ofcocaine. Glutamatergic neurotransmission also appears to be involved in the extinction ofand relapse to cocaine-seeking.This chapter will review the clinical efficacy of medications with glutamatergicmechanisms of action for the treatment of cocaine addiction. Evidence from preclinicalanimal studies demonstrating potential efficacy of novel glutamatergic compounds for thetreatment of cocaine addiction will also be reviewed.

Original languageEnglish (US)
Title of host publicationCocaine Abuse
Subtitle of host publicationPharmacology, Treatment and Relapse Prevention
PublisherNova Science Publishers, Inc.
Pages115-130
Number of pages16
ISBN (Print)9781619422025
StatePublished - Dec 1 2012

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Medications for the treatment of cocaine addiction: Focus on glutamatergic compounds'. Together they form a unique fingerprint.

  • Cite this

    Nemirovsky, N. E., & Olive, M. (2012). Medications for the treatment of cocaine addiction: Focus on glutamatergic compounds. In Cocaine Abuse: Pharmacology, Treatment and Relapse Prevention (pp. 115-130). Nova Science Publishers, Inc..